News & Updates
Filter by Specialty:
Vebicorvir plus entecavir safe, effective in chronic HBV patients
The addition of vebicorvir to entecavir in treatment-naïve patients with chronic hepatitis B virus (HBV) infection provides further antiviral activity, with a positive safety and tolerability profile, results of a phase II trial have shown.
Vebicorvir plus entecavir safe, effective in chronic HBV patients
03 Nov 2022
NADIM II suggests PFS, OS benefits of nivolumab + chemo in resectable NSCLC
Adding nivolumab to paclitaxel-carboplatin chemotherapy in the neoadjuvant setting boosted progression-free survival (PFS) and overall survival (OS) in patients with resectable stage IIIA–B non-small cell lung cancer (NSCLC), according to results of the phase II NADIM II trial from Spain.
NADIM II suggests PFS, OS benefits of nivolumab + chemo in resectable NSCLC
02 Nov 2022
Extended-release nifedipine benefits women with severe pre-eclampsia
Treatment with extended-release nifedipine helps reduce intrapartum acute hypertensive therapy among pre-eclampsia patients with severe features, as reported in a study.
Extended-release nifedipine benefits women with severe pre-eclampsia
02 Nov 2022
Finerenone shields against pneumonia, COVID-19 in diabetic patients with CKD
Patients with concomitant chronic kidney disease (CKD) and type 2 diabetes (T2D) who are undergoing mineralocorticoid receptor blockade with finerenone are better protected against pneumonia and COVID-19, according to a secondary analysis of data from the FIDELITY trials.
Finerenone shields against pneumonia, COVID-19 in diabetic patients with CKD
02 Nov 2022
TNF inhibition beyond 24 weeks: How safe in pregnant mums?
Continued treatment with tumor necrosis factor (TNF) inhibitors after 24 weeks of pregnancy appears safe and is associated with lower chances of maternal inflammatory bowel disease (IBD) relapse, without increasing adverse neonatal outcomes, new research suggests.
TNF inhibition beyond 24 weeks: How safe in pregnant mums?
02 Nov 2022
Oral GnRH antagonists effective in endometriosis-related pain, dysmenorrhea
Oral gonadotropin-releasing hormone (GnRH) antagonists help relieve pain in women with endometriosis or dysmenorrhea, according to the results of a meta-analysis.
Oral GnRH antagonists effective in endometriosis-related pain, dysmenorrhea
01 Nov 2022
4 anti-obesity meds: AGA top picks
Obese adults with weight-related complications who do not respond adequately to lifestyle interventions should be offered one of four anti-obesity medications, according to the new clinical practice guideline on pharmacological interventions released by the American Gastroenterological Association (AGA).
4 anti-obesity meds: AGA top picks
01 Nov 2022
Nelonemdaz safe but fails to improve outcomes in stroke
Treatment with nelonemdaz, a multitarget neuroprotectant that selectively blocks N-methyl-D-aspartate receptors and scavenges free radicals, does not appear to significantly improve stroke outcomes as compared with placebo, although nelonemdaz-treated patients show a greater tendency toward achieving modified Rankin Scale scores of 0–2 at 12 weeks, according to the results of a phase II study.